eXoZymes (NASDAQ:EXOZ) Trading Up 5.5% - Here's Why

eXoZymes Inc. (NASDAQ:EXOZ - Get Free Report)'s stock price shot up 5.5% on Tuesday . The stock traded as high as $11.25 and last traded at $11.25. 3,006 shares changed hands during trading, a decline of 17% from the average session volume of 3,609 shares. The stock had previously closed at $10.66.Analyst Ratings ChangesSeparately, Weiss Ratings reiterated a "sell (d-)" rating on shares of eXoZymes in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, eXoZymes has an average rating of "Sell".Get Our Latest Analysis on EXOZeXoZymes Price PerformanceThe company has a quick ratio of 4.53, a current ratio of 4.53 and a debt-to-equity ratio of 0.01. The stock's 50-day moving average price is $12.21 and its 200 day moving average price is $12.26. The firm has a market cap of $94.50 million, a price-to-earnings ratio of -14.61 and a beta of 2.36. eXoZymes (NASDAQ:EXOZ - Get Free Report) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.27) earnings per share (EPS) for the quarter. About eXoZymes (Get Free Report)eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company's enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows. Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards. eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.Read MoreFive stocks we like better than eXoZymesYour Bank Account Is No Longer SafeRay Dalio Says Buy Gold. I Say Get Paid Every Month From It1 Hour Once A DayWhat a Former CIA Agent Knows About the Coming CollapseThey just tried to kill goldThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in eXoZymes Right Now?Before you consider eXoZymes, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and eXoZymes wasn't on the list.While eXoZymes currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here